drugset / Trial / NCT02554695

Osteoclast Inhibition and Bone Formation

NCT02554695

Phase 0 Completed 81 enrolled Mayo Clinic
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?

Timeline

Start
2015-10-20
Primary completion
2016-10-25
Completion
2016-10-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications